Marchand, P.
Professeur - Responsable de département
Publications
P300
RSC Med. Chem. 2025, 16, 3746–3763.
Pharmacophore-guided optimization of the hit compound CTN1122 in the design of promising imidazo[1,2-a]pyrazine derivatives targeting the casein kinase 1 for antileishmanial therapy
https://doi.org/10.1039/D5MD00257E
P290
ChemMedChem. 2025, 20, e202400862.
Investigating the C2 modulation of the imidazo[1,2-a]pyrazine-based hit compound CTN1122: synthesis, in vitro antileishmanial activity, cytotoxicity and casein kinase 1 inhibition.
https://doi.org/10.1002/cmdc.202400862
P289
Pharmaceuticals. 2025, 18, 125.
2-Aminothiophene derivatives -New drug canditates against leismaniasis: Drug design, synthesis, pharmacomodulation, and antileishmanial activity.
https://doi.org/10.3390/ph18010125
P287
Eur. J. Med. Chem. Rep. 2024, 12, 100228.
Biological properties and in silico studies of thiazolopyrimidine derivatives active against visceral and cutaneous Leishmania spp. amastigote forms.
https://doi.org/10.1016/j.ejmcr.2024.100228.
P279
Pharmaceuticals 2024, 17, 516.
FRET Assays for the Identification of C. albicans HSP90-Sba1 and Human HSP90α-p23 Binding Inhibitors.
https://doi.org/10.3390/ph17040516
P275
Microorganisms 2023, 11, 2837.
Is the C-terminal domain an effective and selective target for the design of Hsp90 inhibitors against Candida yeast?
https://doi.org/10.3390/microorganisms11122837
P269
Nat. Prod. Res. 2023
Phytochemical, antileishmanial, antifungal and cytotoxic profiles of Thymelaea tartonraira (L.) All. extracts.
https://doi.org/10.1080/14786419.2023.2252153
P268
Future Microbiol. 2023, 18, 1225-1233.
Antifungal efficacy of imidazo[1,2-a]pyrazine based thiosemicarbazones and thiazolidinediones against Sporothrix species.
https://doi.org/10.2217/fmb-2023-0044
P267
Chem. Biodivers. 2023, 20, e202200944;
New specific α-glucosidase inhibitor flavonoid from Thymelaea tartonraira leaves: structure elucidation, biological and molecular docking studies.
https://doi.org/10.1002/cbdv.202200944
P250
Phytochem. Lett. 2022, 50, 57-60.
Amino ether analogues of 4,4′-dihydroxy-3-methoxy-6,7′-cyclolignan and their activity against drug-resistant bacteria.
https://doi.org/10.1016/j.phytol.2022.05.004
P244
Letter to the Editor, Quim. Nova 2022, 45, 1-3.
The Franco-Brazilian Network on Natural Products (FB2NP): a new network promoting cooperation and exchanges in natural products research.
https://doi.org/10.21577/0100-4042.20170847
P240
Molecules 2021, 26, 6572.
Dibenzofuran derivatives inspired from cercosporamide as dual inhibitors of Pim and CLK1 kinases.
doi: 10.3390/molecules26216572
P239
Chem. Biol. Interact. 2021, 347, 109597.
Synthesis, anticancer activity and mechanism of action of new phthalimido-1,3-thiazole derivatives.
doi: 10.1016/j.cbi.2021.109597
P237
Phytochem. Lett. 2021, 43, 212-218.
New cyclolignans of Larrea tridentata and their antibacterial and cytotoxic activities.
doi: 10.1016/j.phytol.2021.04.013
P234
Med. Chem. Res. 2021, 30, 152-162.
Antimicrobial and anti-leishmanial activities of extracts and some constituents from the leaves of Solanum chrysotrichum Schldl.
doi: 10.1007/s00044-020-02648-8
P232
Chem. Biol. Interact. 2021, 333, 109316.
Streptomyces hygroscopicus UFPEDA 3370: a valuable source of the potent cytotoxic agent nigericin and its evaluation against human colorectal cancer cells.
doi: 10.1016/j.cbi.2020.109316
P231
Eur. J. Med. Chem. 2021, 210, 112956.
In vitro identification of imidazo[1,2-a]pyrazine-based antileishmanial agents and evaluation of L. major casein kinase 1 inhibition.
doi: 10.1016/j.ejmech.2020.112956
P222
Pharmaceuticals. 2020, 13, 202.
Microwave-assisted synthesis of potential bioactive benzo-, pyrido- or pyrazino-thieno[3,2-d]pyrimidin-4-amine analogs of MPC-6827.
doi: 10.3390/ph13090202
P219
Pharmaceuticals 2020, 13, 89.
Exploring kinase inhibition properties of 9H-pyrimido[5,4-b]- and [4,5-b]indol-4-amine derivatives.
doi: 10.3390/ph13050089
P205
Pharmaceuticals 2019, 12, 182;
A decade of antifungal leads from natural products: 2010-2019.
doi:10.3390/ph12040182.
Autres publications scientifiques
PS37
J. Med. Chem. 2025, 68, 2045–2047.
Shaping future medicinal chemists: Perspectives from European schools of Pharmacy within the GP2A network.
https://doi.org/10.1021/acs.jmedchem.4c03103
PS36
Pharmaceuticals 2025, 18, 837.
New insights into the anticancer effects and toxicogenomic safety of two β-Lapachone derivatives.
https://doi.org/10.3390/ph18060837
PS09
Antiinflamm. Antiallergy Agents Med. Chem. 2022, 21, 135-151.
Effects of acylhydrazone derivatives on experimental pulmonary inflammation by chemical sensitization.
https://doi.org/10.2174/1871523021666220729141608
PS04
Curr. Top. Med. Chem. 2022, 22, 247-258.
Antinociceptive effects of aza-bicyclic isoxazoline-acylhydrazone derivatives in different models of nociception in mice.
https://doi.org/10.2174/1568026622666220105102508
Brevets
B12.
Nouveaux dérivés indoliques, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
Brevet Français, déposé le 18 octobre 2006, sous le n° 06/09114.
B11.
Nouveaux dérivés indoliques, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
Brevet Français, déposé le 18 octobre 2006, sous le n° 06/09113.
B15.
Novel Naphthyridine derivatives and the use thereof as kinase inhibitors.
PCT Int. Appl. WO 2011064250, 2011.
Thèse
T01.
Synthèse et évaluation pharmacologique de dérivés indoliques à activités immunosuppressive et antitumorale.
Nantes, 23 novembre 1999.